Compound 13 showed significantly enhanced inhibition potency against MYC-amplified SCLCs than MYC-unamplifiedSCLCs and tumor growth inhibition activity in a cMYC-amplified SCLC cell line NCI-H446 xenograft mouse model when administeredintravenously. Here, MYC is linked to neoplasm.